Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab +/- Interferon alfa-2a in Indolent Lymphoma
NCT01609010Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2002
- Primary completion
- Jul 2011
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
A Phase 3 trial of interferon alfa-2a in follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), lymphoma, sponsored by Roche. Started Oct 2002; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)lymphoma
Beyond the preview
Go deeper on NCT01609010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609010.